Ionis CEO: Trump's Drug Price Push Offers No Upside for Mid-Sized Pharma
IONS has more than doubled off its 52-week low of $39.37.
Summary
Ionis Pharmaceuticals and other mid-sized drugmakers are resisting the Trump administration's Medicaid pilot program aimed at lowering drug prices. Ionis CEO Brett Monia stated the company sees no upside in participating, noting that price cuts could dramatically impact their bottom line due to their different business model compared to large pharma. This policy risk emerges after a period of strong positive news for Ionis, including recent FDA approvals and robust Q1 earnings. Companies not participating in the voluntary Medicaid program could face potentially mandatory CMS pilot programs for Medicare as soon as October, which could significantly limit pricing autonomy.
At the time of this announcement, IONS was trading at $81.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3B. The 52-week trading range was $39.37 to $86.74. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.